GlassScriptPhysician profile
Jason Burl Hicks
NPI 1023034097
$1,189.01
in general payments reported to CMS, 2019-2025
25 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $95.31 · 2023: $185 · 2024: $338 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169.40 | 2019-2025 | |
| Pfizer INC. | $160.47 | 2019-2025 | |
| Sanofi Pasteur INC. | $157.58 | 2019-2025 | |
| Novo Nordisk INC | $138.10 | 2023-2025 | Ozempic, Rybelsus |
| Tris Pharma INC | $66.51 | 2019 | |
| Merck Sharp & Dohme LLC | $61.98 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaqta |
| Takeda Pharmaceuticals U.S.A., INC. | $52.87 | 2019-2020 | |
| Seqirus USA INC | $42.40 | 2024-2025 | Flucelvax, Fluad |
| Lilly USA, LLC | $42.12 | 2024 | Mounjaro |
| Shire North American Group INC | $38.05 | 2019 | |
| Ironshore Pharmaceuticals INC. | $31.71 | 2019 | |
| Glaxosmithkline, LLC. | $26.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $22.31 | 2024 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $20.90 | 2025 | Jornay Pm |
| Abbott Laboratories | $19.72 | 2023 | Freestyle Libre 2 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.51 | 2020 | |
| Shield Therapeutics INC | $15.30 | 2023 | Accrufer |
| Genentech USA, INC. | $15.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.06 | 2019 | |
| Currax Pharmaceuticals LLC | $13.89 | 2024 | Contrave, Onzetra Xsail |
| Allergan, INC. | $13.87 | 2019 | |
| Adlon Therapeutics L.P. | $13.40 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.40 | 2019 | |
| Sobi, INC | $12.13 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.